The rise of new psychoactive substances and psychiatric implications: A wide-ranging, multifaceted challenge that needs far-reaching common legislative strategies.

Human Psychopharmacology
Raffaella RinaldiS Zaami

Abstract

The ever-growing number of novel psychoactive substances (NPS) that have been surfacing globally, as well as related changes in drug abuse trends, undoubtedly constitute a difficult and multifaceted challenge for psychiatry. The intake and abuse of such substances has been linked to a risk of psychopathological disturbances, which stem from imbalances of a range of neurotransmitter pathways and receptors. Through an analysis of relevant research articles and reviews (particularly those outlining NPS neurological and cerebral mechanisms of action and psychopathological consequences arising from NPS abuse; research papers more closely focused on chemical/pharmacological aspects have been ruled out), through a systematic analysis of Pubmed, Medline, PsycLIT and EMBASE literature, as well as data released by health care institutions and drug enforcement agencies (among which the World Health Organization, the United Nations Office on Drugs and Crime, the European Monitoring Centre for Drugs and Drug Addiction, Eurojust, the Novel Psychoactive Treatment UK Network, the Court of Justice of the European Union), the authors aimed to elaborate on the most relevant data relative to NPS-related psychiatric effects, focusing on the concept...Continue Reading

References

Oct 12, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C Schmidt-MutterM Maitre
Oct 9, 2007·Drug and Alcohol Dependence·Chalon R Majewski-TiedekenSteven J Siegel
Nov 19, 2008·Substance Use & Misuse·Steve SussmanSusan L Ames
Nov 13, 2010·Psychopharmacology·Fabrizio SchifanoUNKNOWN ReDNet Research Groups
Dec 21, 2010·The Journal of Emergency Medicine·Aaron B SchneirBinh T Ly
Feb 15, 2011·Drug and Alcohol Dependence·Susanna Every-Palmer
Oct 6, 2011·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Simon L Hill, Simon H L Thomas
Feb 22, 2012·The International Journal on Drug Policy·Alasdair J M Forsyth
Aug 18, 2012·British Journal of Pharmacology·L D SimmlerM E Liechti
Jan 22, 2013·The International Journal on Drug Policy·Stephen J BrightMonica J Barratt
Jan 29, 2014·Drug Testing and Analysis·Claudio Vidal GinéMireia Ventura Vilamala
Feb 4, 2014·Advances in Pharmacology·Leonard L Howell, S Stevens Negus
Mar 29, 2014·Drug Testing and Analysis·Hamilton Morris, Jason Wallach
Apr 18, 2014·Basic & Clinical Pharmacology & Toxicology·Louise KarlssonFredrik C Kugelberg
Jun 27, 2014·Substance Abuse and Rehabilitation·Magalie Paillet-LoilierDanièle Debruyne
Jul 29, 2015·Human Psychopharmacology·Barbara LoiFabrizio Schifano
Aug 25, 2015·The International Journal on Drug Policy·A BourneP Weatherburn
Oct 27, 2015·Neurotoxicity Research·Krystyna GołembiowskaAnna Górska
Nov 17, 2015·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Robert J TaitSimon Lenton
Jan 28, 2016·Current Neuropharmacology·Francesco Paolo BusardòPaola Frati
Feb 19, 2016·Drug Testing and Analysis·Tibor M BruntMireia Ventura Vilamala
May 21, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Esther PapaseitMagí Farré
Jul 28, 2016·Journal of Addictive Diseases·Rama M KamalCornelis A J de Jong
Sep 13, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Nabi ZorluChristos Pantelis
Nov 12, 2016·Current Neuropharmacology·Chrystalla KyriakouSimona Zaami
Dec 14, 2016·The International Journal on Drug Policy·Alessandro PironaJane Mounteney
Jan 27, 2017·Journal of Addiction Medicine·Louis von TheobaldMarie Grall-Bronnec
Apr 21, 2017·British Journal of Pharmacology·L-S Camilla d'AngeloBarbara J Sahakian
Jul 13, 2017·Current Pharmaceutical Biotechnology·Renata SoliminiSimona Zaami
Aug 2, 2017·Neuropharmacology·Dino LuethiMatthias E Liechti
Aug 2, 2017·Clinical Chemistry and Laboratory Medicine : CCLM·Francesco Paolo BusardòPascal Kintz
Aug 24, 2017·Neuropharmacology·Michael D BerquistWilliam E Fantegrossi
Nov 4, 2017·Pharmacology & Therapeutics·Laura HondebrinkRemco H S Westerink
Jan 26, 2018·HIV Medicine·E L PufallUNKNOWN Positive Voices study group
Sep 9, 2018·Handbook of Experimental Pharmacology·Michael Evans-Brown, Roumen Sedefov
Sep 27, 2018·Current Drug Metabolism·Francesco Paolo BusardòSimona Zaami
Jan 22, 2019·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Jasmin GriggDan I Lubman

❮ Previous
Next ❯

Citations

Jul 2, 2020·Critical Reviews in Clinical Laboratory Sciences·Bhushan M Kapur, Katarina Aleksa
Aug 9, 2020·Frontiers in Psychiatry·Simona ZaamiMaria Rosaria Varì
Jan 9, 2021·Therapeutic Advances in Psychopharmacology·Abu ShafiDerek K Tracy
Aug 15, 2021·Journal of Pharmaceutical and Biomedical Analysis·Franks Kamgang NzekoueSimone Lucarini

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.